Abstract 12665: ‰Real-World Comparison of 2-year Clinical Outcomes Between First Generation and Second Generation Drug-eluting Stents in Asian Population
Background: There have been few studies comparing the efficacy and safety of 1st and 2nd generation drug-eluting stents (DESs) and their 2-year clinical outcomes in real world clinical practice at all comer base specifically in Asian population.
Methods: A total 1,567 consecutive patients (pts) underwent percutaneous coronary intervention (PCI) with 1st & 2nd generation DESs between 2005 and 2009 were enrolled. We compared 6-month angiographic and 2-year major clinical outcomes of pts treated with 1st generation DESs [DES-1; sirolimus (n=527)- and paclitaxel (n=554)-eluting stents, n=1081)] versus 2nd generation DESs [DES-2; zotarolimus (n=371)- and everolimus (n=115)-eluting stents, n=486).
Results: Baseline characteristics were similar between the two groups except use of cilostazol, chronic renal insufficiency was higher and the total stent length was longer in the DES-1 group whereas diabetes mellitus was higher in the DES-2 group. At 6- month angiographic outcomes were similar between the two groups. Further, after adjustment of baseline confounders, major clinical outcomeswere similar between the two groups at 2-years (table).
Conclusions: In our study, mid-term angiographic and 2-year major clinical outcomes were similar between the first (sirolimus and paclitaxel) and second (zotarolimus and everolimus) generation DESs in all comer real world clinical practice in a series of Asian population.
- © 2012 by American Heart Association, Inc.